Mrs
Karen
Russell

Senior Patent Attorney

Manchester Office

Life sciences

Telephone. +44(0) 161 247 4900
Email. [email protected]
Vcard
Linkedin

Experience

Bringing over 20 years’ experience in private practice, Karen specialises in the fields of life sciences and pharmaceuticals. Having started her career in London, she joined HGF in 2010 and enjoys being an active member of the biotech and chemical teams in the Manchester office.

Karen’s experience covers a wide range of biotechnological and biopharmaceutical subject matter including nucleic acid and peptide based therapeutics. She has a particular interest in SPCs, and her practice includes filing and prosecution of SPC applications in both the medicinal and agrochemical fields.

In the course of her career, she has worked with a variety of clients, including universities, SMEs and large multi-nationals, providing guidance in patent prosecution before the EPO and internationally, as well as advice relating to patentability, freedom to operate, and SPC filings.

Karen holds an MA in Natural Sciences (Biological), and an MPhil in Biotechnology, both from the University of Cambridge. Her MPhil research investigated the genetic basis for the microbial degradation of cocaine.

Specialisms

Industries

Services

Qualifications

Patent Attorney

Chartered (UK)
European

MA

Natural Sciences (Cantab)

POSTGRADUATE DIPLOMA OR CERTIFICATE

Queen Mary and Westfield College Certificate in Intellectual Property Law

OTHER

MPhil Biotechnology (Cantab)

Publications

A Step Towards A Unitary SPC?

View publication online

EU SPC waiver for generic pharmaceuticals producers

View publication online

Conferences: 2020

November 17th 2020

2020 CIPA Life Sciences Webinar Series (2020 CIPA Life Sciences Conference)

Attended

Related News

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details
Event - 10th March 2022

Manufacturing & Supply Chain Conference 2022

HGF Patent Attorney Dr Robert Weinert-Aplin is attending and speaking at the Manufacturing & Supply Chain Conference on 10th March 2022 in Milton Keynes, UK. The Manufacturing & Supply Chain …

Event details

The Microbiome Times: ELIGO v SNIPR: a reflection on IP strategies in a competitive environment

HGF Partner and Patent Attorney Craig Thomson and Patent Director Dr Jennifer Bailey write an article for The Microbiome Times on ELIGO v SNIPR: a reflection on IP strategies in …

Read article

UPC could open its doors in 2022

With news that the Austrian parliament has ratified the Protocol on the provisional application of the Agreement on a Unified Patent Court on 2 December 2021, the Unified Patent Court …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us